ONLINE SURVEY – Artificial Intelligence in Research & Development

BIO Deutschland in collaboration with Reutlingen University and the University of St. Gallen is launching an industry survey to the hot topic of artificial intelligence (AI) in pharma R&D.

Technology giants, such as Google, Amazon, Microsoft and IBM are leading companies in the field of AI and will revolutionize the healthcare, pharma and biotech sectors in the coming years. Some pharma companies, e.g. Novartis, have already developed a digital strategy and are dedicated to use the potential of AI and other digital technologies -  biomedical research & development (R&D) is a key focus area. The relevance of AI is indicated by a projected pharma market potential of USD 10 billion by 2024 or a foreseen 10-25% clinical trials costs reduction.

BIO Deutschland in collaboration with Reutlingen University and the University of St. Gallen is addressing this online survey (covering the use, value propositions and risks of AI in R&D) to research-based small, medium-sized and big companies in the biomedical sector as well as to service providers in these areas.

Your time invest is 10-20 minutes. The survey and the evaluation strictly adhere to the General Data Protection Regulation. All respondents will remain completely anonymous. All participants will receive a final anonymized report summarizing the outcomes. The results will also be used for the academic work of the study directors and be published in an anonymized form in a scientific journal, if the quantity and quality of data is sufficient.
Are you interested in this hot topic, please participate in the online survey by using the following link www.umfrageonline.com/s/a6c11f9 or by contacting the directors of the study

Prof. Dr. Alexander Schuhmacher
Reutlingen University
E-mail: alexander.schuhmacher@reutlingen-university.de

and  

Prof. Dr. Oliver Gassmann
University of St. Gallen
E-mail: oliver.gassmann@unisg.ch